期刊文献+

盐酸阿夫唑嗪微孔渗透泵控释片的研制及释药影响因素考察

Preparation of alfuzosin hydrochloride porosity osmotic pump tablets and study on factors influencing drug release
下载PDF
导出
摘要 目的制备盐酸阿夫唑嗪微孔渗透泵型控释片,并考察其体外释药的影响因素。方法以醋酸纤维素为膜材,聚乙二醇-400为致孔剂,邻苯二甲酸二丁酯为增塑剂,制备微孔渗透泵片,通过单因素考察影响释药的处方因素,并采用相似因子为指标通过正交设计筛选处方。结果促渗剂的种类、包衣膜厚度、致孔剂和增塑剂的量是影响释药的主要因素。结论制备了盐酸阿夫唑嗪微孔渗透泵控释片,12 h内呈现明显的恒速释药。 Objectives To prepare alfuzosin hydrochloride porosity osmotic pump tablets and investigate factors influencing the drug release.Methods Cellulose acetate(CA) was used as the semipermeable membrane and PEG-400 was chosen as channeling agents.The factor influencing the drug investigated was selected by the single factor study and the optimal formulation of alfuzosin hydrochloride porosity osmotic pump tablets was screened by an orthogonal design.Results Coating level,channeling agents and plasticizer were all found to have great effect on the in vitro release of porosity osmotic pump tablets.Conclusions The tablets with optimized formulation could achieve the desired zero- order release profile in 12 hours.
出处 《中国药剂学杂志(网络版)》 2007年第5期234-240,共7页 Chinese Journal of Pharmaceutics:Online Edition
关键词 药剂学 盐酸阿夫唑嗪 微孔渗透泵片 控制释放 pharmaceutics alfuzosin hydrochloride porosity osmotic pump tablets controlled release
  • 相关文献

参考文献8

  • 1刘云,张钧寿,胡林森.布地奈德结肠定位微丸的制备及释药特性研究[J].中国药科大学学报,2003,34(5):419-422. 被引量:8
  • 2傅崇东,徐惠南,张瑜.pH依赖-缓释型美沙拉秦结肠靶向小丸的制备与体外评价[J].中国医药工业杂志,2000,31(12):541-544. 被引量:31
  • 3吴涛,潘卫三,庄殿友,陈济民.口服渗透泵制剂的研究进展[J].中国药学杂志,1999,34(2):76-78. 被引量:28
  • 4柏俊,孙备,吕凌.甲硝唑结肠定位缓释制剂[P]中国专利:CN1398587.
  • 5Sapna N Makhija,Pradeep R Vavia.Controlled porosity osmotic pump-based controlled release systems of pseudoephedrine[J]. Journal of Controlled Release . 2003 (1)
  • 6Vinod P. Shah,Yi Tsong,Pradeep Sathe,Jen-Pei Liu.In Vitro Dissolution Profile Comparison—Statistics and Analysis of the Similarity Factor, f2[J]. Pharmaceutical Research . 1998 (6)
  • 7Gaylen M. Zentner,Gerald S. Rork,Kenneth J. Himmelstein.Osmotic flow through controlled porosity films: An approach to delivery of water soluble compounds. Journal of Controlled Release . 1985
  • 8Zentner GM,Rork GS,Himmelstein KJ.The controlled porosity osmotic pump. Journal of Controlled Release . 1985

二级参考文献8

  • 1Nagent, Ranpton, Evans, et al. Intestinal Iuminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs[J]. Gut ,2001 ; 48:571-577.
  • 2Markus WR, Klein S, Thomas EB ,et al. A new 5-aminosalicylic acid multi-unit dosage from for the therapy of ulcerative colitis[J].Eur J Pharm, 2001, 51:183-190.
  • 3Evans DF, Pye G, Bramley R, et al,Measurement of gastrointestinal pH profiles in normal ambulant human subjects[J]. Gut,1988,29:1035-41.
  • 4Rodriguez M, Jose L, Vila-Jato, et al. Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region[J]. J Control Release ,1998,55:67-77.
  • 5Ashford M, Fell JT, Attwood D, et al. An in vitro investigation into the suitability of pH-dependent polymers for colonic targeting[J]. Int J Pharm, 1993,93:193-199.
  • 6Caroline MS,Donna MT,Budesonide[J],Drugs, 1995,59(5):854-872.
  • 7Peter JW, Lisheth L. Colonic drag delivery[ J ]. Drug Dev Indus Pharm, 1997, 23(9): 893-913.
  • 8傅崇东,徐惠南,张瑜.5-氨基水杨酸与其结肠靶向制剂[J].上海医药,1999,20(4):29-30. 被引量:14

共引文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部